Study on the rules of TCM syndromes and Chinese herbal medicines about IgAN based on data mining

• 作者: Hong-Tong Chen Cai-Di Gong Chong Xiong Jian Zhong Zi-Xia Wang Ping Chen
• 来源期刊: 海南医科大学学报（英文版）
• 年，卷（期）: 2021,（12）
• 所属期刊栏目: Original article
• 页码范围: 38-42
• 页数: 5页
• 语种: 英文

摘要

Objective: To analyze the clinical research literatures of TCM syndromes and treatment of Immunoglobulin A Nephropathy (IgAN) on data-mining technology, and explore the rules of TCM syndromes and Chinese medication. Methods: By searching the clinical literatures about TCM syndromes and treatment of IgAN had published in China Biomedical Literature Database, CNKI Database, Wanfang Database, and Chongqing Weipu Database from January 2000 to September 2019. Strictly according to the inclusion and exclusion criteria, included documents and established the databases. Applicated of statistical software for frequency analysis of TCM syndromes, Chinese herbal medicines, and analyzed the commonly used Chinese herbal medicines by factor analysis and cluster analysis. Results: 292 literatures were finally included, involving 28 syndromes. A total of 479 prescriptions and 254 Chinese herbs were used. The rules of syndromes in IgA nephropathy are as follows: the syndromes are mainly composed of Qi and Yin deficiency syndrome, followed by the Spleen and kidney qi deficiency syndrome, Liver and Kidney Yin Deficiency Syndrome, Spleen and kidney yang deficiency syndrome. The blood-stasis syndrome, damp-heat syndrome and wind-heat disturbance syndrome are accompanied by other syndrome. The characteristics of traditional Chinese medicines for IgA nephropathy is mainly composed of tonic deficiency medicines, supplemented by blood-activating and stasis-eliminating medicines, heat-clearing medicines, inducing diuresis and excreting dampness medicines and astringent medicines to combine with formulas. Conclusion: Through Data-mining method systematically summarized the rules of TCM syndromes and Chinese medication in treating IgAN and provided scientific theoretical guidance for the treatment of IgAN.